# Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial

Source: https://onco.cc/key-papers/paper-protect-bju-int-2026-update/  
OnCo record `paper-protect-bju-int-2026-update` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Later report from the ProtecT trial registered as NCT02044172, in BJU international (2026); its title describes an updated or longer-term analysis.

## Summary

Objectives: To retrospectively analyse the results of the Prostate Testing for Cancer and Treatment (ProtecT; ClinicalTrials.gov identifier: NCT02044172) trial to establish the association between cribriform-positive and -negative prostate cancer (PCa) and the 15-year risk of metastasis or death from PCa in patients who underwent radical prostatectomy (RP).

Patients and methods: Between 1999 and 2009, the ProtecT phase 3 clinical trial enrolled 1643 men with clinically localised PCa who were randomised to receive active monitoring, RP, or radiotherapy. In this secondary analysis of the trial, a centralised histopathological review was conducted on available RP pathology slides to classify patients as cribriform-positive if they had invasive cribriform carcinoma and/or intraductal carcinoma. The primary outcome was a composite of progression to metastatic disease or death from PCa. Exposures included age, prostate-specific antigen density, RP Grade Group (GG), pathological T stage (pT), and cribriform status. Multivariable Cox proportional hazards regression models assessed 15-year risk. Cumulative incidence curves were compared using the Gray test.

Results: Of 480 men with RP specimens reviewed, 143 (30%) had cribriform-positive disease and 337 (70%) had cribriform-negative disease. All 21 metastatic or lethal events occurred exclusively in the cribriform-positive group (15-year cumulative incidence 14%). Within the cribriform-positive cohort, risk was concentrated in patients with pT3b stage and/or GG ≥3 (15-year cumulative incidence 27%). In multivariable analysis of cribriform-positive patients, pT3b stage (hazard ratio [HR] 8.19, 95% confidence interval [CI] 2.39-28.10; P < 0.001) and GG 3 disease (HR 5.12, 95% CI 1.59-16.40; P = 0.006) were independent predictors of adverse outcomes. Conversely, cribriform-positive patients with GG 2 and ≤pT3a had a 15-year event rate of only 3%.

Conclusion: In the ProtecT trial, the 15-year risk of metastasis or death after RP was a binary outcome defined by cribriform status. The concentration of risk in men with cribriform-positive, high-grade and/or pT3b tumours identifies a target population for adjuvant therapy trials, while supporting management de-escalation for most RP patients.

Indexed on Europe PMC as PubMed record 41896701 (DOI 10.1111/bju.70261). Its abstract cites the registry id NCT02044172, which is how it was matched to this trial; no figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: BJU international
- Year: 2026
- DOI: 10.1111/bju.70261
- Authors: Sushentsev N, Warren AY, Colling R, et al.
- What it means: A second publication from the ProtecT trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
- Caveats: Matched to the trial by the registry id cited in the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.; Chosen as a later report by words in its title (updated, long-term, final, overall survival or a year count), not by reading the paper.

## Sources

- BJU Int 2026: https://doi.org/10.1111/bju.70261
- PubMed: https://pubmed.ncbi.nlm.nih.gov/41896701/
- Europe PMC: https://europepmc.org/article/MED/41896701
- ClinicalTrials.gov NCT02044172: https://clinicaltrials.gov/study/NCT02044172

## Connected records

- trials: [ProtecT](https://onco.cc/trials/protect/)

---
JSON: https://onco.cc/api/v1/entities/paper-protect-bju-int-2026-update.json